Inari Medical, Inc. (NARI)
Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Inari Medical, Inc. (“Inari” or “the Company”) (NASDAQ: NARI) and certain of its officers.
Class Definition:
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Inari securities between February 24, 2022 and February 28, 2024, inclusive (the “Class Period”). Such investors are encouraged to join this case.
Case Details:
The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Inari is a medical device company that develops and manufactures various products, including minimally invasive, novel, catheter-based mechanical thrombectomy devices and their accessories to address the unique characteristics of specific medical conditions. These products aim to improve outcomes for patients suffering from venous thromboembolism (“VTE”) and other vascular diseases and conditions. During the Class Period, Defendants consistently touted Inari’s “record revenue,” purportedly driven by “the strength in our core VTE business.” However, the Complaint alleges that Defendants failed to disclose that a significant portion of its expenses were used to compensate medical professionals improperly for using Inari’s products. The Complaint continues to allege that in truth, while Defendants were speaking positively about the Company’s growth prospects, it had been engaging in illegal business practices, and that the Company had been unlawfully compensating health care professionals in violation of the federal Anti-Kickback Statute and Civil False Claims Act. Finally, the Complaint alleges that Defendants also misled investors regarding business expenses to conceal their illicit conduct.
What’s Next?
A class action lawsuit has already been filed. You may review a copy of the Complaint. You may also contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660. If you suffered a loss in Inari you have until July 12, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,